Form 4: Vor Biopharma CFO Equity Shift: Options Replace RSUs

Vor Biopharma's CFO, Sandesh Mahatme, reported the cancellation of restricted stock units and the grant of new stock options following a reverse stock split.

Summary

• Sandesh Mahatme, CFO of Vor Biopharma Inc. (VOR), reported changes in his beneficial ownership of company securities.
• On December 5, 2025, the Compensation Committee of the Board of Directors approved the cancellation of a previously awarded grant of 694,137 restricted stock units (RSUs), which had been reported on a Form 4 filed July 10, 2025.
• Concurrently, on December 5, 2025, Mr. Mahatme was granted 1,388,274 employee stock options.
• The exercise price for these options is $17.80 per share, or $8.18 per share if exercised after the 'Retention Period'.
• The 'Retention Period' begins on December 5, 2025, and ends on the earlier of December 5, 2027, or a Change in Control during Mr. Mahatme's continuous service.
• One-fourth (1/4th) of the shares underlying the option will vest on July 1, 2026, with the remaining shares vesting in equal monthly installments over the subsequent three years, all subject to Mr. Mahatme's continued service.
• All share counts in the filing reflect a 1-for-20 reverse stock split effected by the Issuer on September 18, 2025.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. While restricted stock units were cancelled, a larger number of stock options were granted, suggesting a restructuring of long-term incentives rather than a negative event. The reverse stock split is a separate corporate action that provides context for the share counts.

Positives

• The grant of 1,388,274 employee stock options provides a significant long-term incentive for the CFO, aligning his interests with shareholder value creation.
• The multi-year vesting schedule encourages continued service and commitment to the company's long-term success.
• The dual exercise price structure offers potential upside for the CFO, particularly if the stock performs well after the Retention Period.

Negatives

• A previously awarded grant of 694,137 restricted stock units was cancelled, which could be perceived as a reduction in a more immediate form of equity compensation.

Future Outlook

The filing details equity compensation with vesting schedules extending several years into the future, indicating a long-term incentive structure for the CFO that aims to align his interests with the company's sustained performance.

Industry Context

This Form 4 filing represents a routine insider transaction related to executive compensation, a common practice in the biotechnology and pharmaceutical industries. Companies frequently use equity grants, such as stock options, to attract, retain, and incentivize key executives, aligning their financial interests with the long-term success and shareholder value creation of the company. The reverse stock split is a separate corporate action that impacts share counts and per-share metrics.

Corporate Governance

Related Party Transactions

• The transaction involves the grant of equity compensation to Sandesh Mahatme, the Chief Financial Officer of Vor Biopharma Inc., which constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The grant of stock options to the CFO aligns management incentives with long-term shareholder value creation, but also introduces potential future dilution upon exercise. The reverse stock split impacts the number of shares outstanding and per-share metrics, which can influence investor perception.
• Employees: While specific to the CFO, this transaction highlights the company's approach to executive equity compensation, which may reflect broader compensation philosophies for key personnel.

Next Steps

• Continued vesting of the granted stock options for Sandesh Mahatme, subject to his continuous service with Vor Biopharma Inc.
• Potential exercise of vested stock options by Sandesh Mahatme in the future.

Key Dates

Recommendation

This Form 4 primarily details a routine executive compensation adjustment (cancellation of RSUs, grant of options) following a reverse stock split. It does not provide new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. The equity grant is a standard incentive mechanism, and the overall impact on the company's intrinsic value or near-term prospects is neutral.

Keywords

Vor Biopharma, VOR, Sandesh Mahatme, CFO, Form 4, insider transaction, stock options, restricted stock units, equity compensation, reverse stock split, beneficial ownership